Boston Scientific is a leader in producing less-invasive medical devices used in treatments like angioplasty, cardiac rhythm management, blood clot filtration, interventional oncology, and other such essential treatments. The firm has a well-diversified revenue base, with 50% coming from the US and 50% from international markets. An increasing focus on healthcare globally, along with Boston Scientific’s strong brand within the medical community, positions the company well for long-term growth. Investors looking for the best medical stocks today can consider researching Boston Scientific further.
More About Boston Scientific
Boston Scientific was incorporated in the year 1979 in Watertown, Massachusetts. The company went public in the year 1992 and has since grown significantly through acquisitions. Boston Scientific ranks highly on social commitments and diversity. It had 43% women employees in 2018 and was among the top 10 companies in integrating employees of various racial groups, genders, disabled persons, etc. Boston Scientific develops, manufactures, and markets a variety of medical devices. It has been a dominant player in the industry for more than four decades. The areas of healthcare covered by Boston Scientific include urology, endoscopy, cardiac rhythm management, electrophysiology, and specialty pharmaceuticals.
Boston Scientific had 11 major manufacturing facilities as of December 31st, 2020. They were located in the US, Ireland, Costa Rica, Brazil, Malaysia, Israel, UK, and Switzerland. The company also has research and development centers in India, China, Puerto Rico, Ireland, and Costa Rica. Investors looking for the top medical stocks today will find Boston Scientific to be a global medical device powerhouse.
Boston Scientific trades on the New York stock exchange under the ticker symbol BSX. The stock closed at $43.02 on June 18th, 2021. The stock was up against some 23% over the preceding six months. The 52-week high was at $44.63, while the 52-week low was $32.99. The price on June 18th wasn’t far from the 52-week high.